Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
1998-11-11
2001-02-20
Jarvis, William R. A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S262100
Reexamination Certificate
active
06191151
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the treatment of certain herpes viral neurological conditions in mammals, principally Bell's Palsy, a palsy of the facial nerves, and to the use of calcium channel blockers coupled preferably with a herpes virus antagonist in a treatment therapy. Other herpes conditions include Ramsay Hunt and other herpes caused neurological conditions such as Herpes Simplex Encephalitis.
BACKGROUND OF THE INVENTION
Bell's Palsy (originally described by Charles Bell, 1812) is recognized as a palsy of the facial nerve, generally the seventh cranial nerve. It most commonly affects one side of the face, may be partial or total, and has a progression time of 7 to 10 days. Regarded in the past as idiopathic, there has recently been convincing evidence that it has its cause in the herpes type virus of the simplex type. Some physicians reassure patients that the disease will most likely remit in a period lasting from 3 weeks up to 6 months, (leading some physicians to advocate a no action policy other than facial management, sometimes referred to as “therapeutic nihilism”) but the fact remains that about 24% of the victims with current popular therapies are left with some residual paralysis or other aftereffects such as hemi-facial spasm, synkinesis, or loss of tearing or blinking capacity.
An understanding as to the likely physiological events (without an identification of their cause) was comprehensively put forward by Hilger (Hilger J,
The Nature of Bell's Palsy. Laryngoscope,
54:228-235, 1949) and Blunt (Blunt M,
Possible Role of Vascular Changes in the Etiology of Bell's Palsy, J. Laryngol Otol,
70:701-713, 1956)) where they maintained that vasoconstriction of the arterioles within the fallopian aqueduct of the temporal bone was responsible for the facial palsy. This vasoconstriction was believed to lead to primary ischemia (tissue anemia) entailing edema of the nerve sheath and a secondary ischemia due to nerve compression. K. Adour opposed this account and instead put forward a viral theory (Adour K K,
Cranial Polyneuritus and Bell's Palsy, Arch Otolarygol,
102:262-4, 1976) based on herpes simplex reactivation and maintained that Bell's Palsy was polycranial which was believed to be inconsistent with an ischemia scenario. However, support of the former ischemia outlook was provided through anatomical electromyographical and histopathological studies summarized by U. Fisch (Fisch U. and Felix, H,
On the Parthenogenesis of Bell's Palsy. Acta Otolaryngol,
95:532-538, 1983)). Further the ischemia description of events fits well with later causal analysis by M. Ikeda (Ikeda M et al,
Plasma Endothelin Level in the Acute Stage of Bell Palsy, Arch Otolyaryngol Head Neck Surg,
122:849-852, August 1996) involving endothelin findings; and work on the immunological role of endothelin has been inferentially linked by the inventor to an ischemia scenario (which requires—a herpes viral role) as will be later explained.
Current therapy mainly involves the administration of steroids, particularly prednisone (see U.S. Pat. No. 2,897,216) within the first 3 days of onset, where the standard initial prednisone dosage is about 30 mg. and is tapered off over a 5 day period to a 10 mg. level. In parts of Japan and Europe the steroid treatment has taken the form of heavier steroid dosages, mainly cortisone, incorporated within an IV infusion of low molecular dextran (Kinishi M et al.,
Conservative Treatment of Hunt Syndrome, Nippon Jibinkoka Gakkai Kaiho,
95:1, 65-70, 1992) (See U.S. Pat. No. 2,841,578). The theory underlying steroid treatment, either by prednisone or the higher dosage method, is to improve microcirculation, which has been impaired due to inflammation affecting the seventh cranial nerve. It may be noted that steroid treatment of the high dosage type has its share of hazards that leave many physicians uncomfortable, and which includes serious hepatic and renal disorders.
Recently a new element of approach that is coupled with steroid therapy has emerged from the work of Dr. Kedar Adour, who for many years had maintained that the herpes simplex virus is the original causal agent in Bell's Palsy. Based on this belief, Adour has advocated the use of acyclovir (See U.S. Pat. No. 2,539,963) (commonly used for treating herpes viral infections) for treating Bell's Palsy. He has in this effort conducted a double blind study (Adour K K et al.,
Bell's Palsy Treatment With Acyclovir And Prednisone Compared With Prednisone Alone: A Double
-
Blind, Randomized Controlled Trial. Otol Rhinol. Larygnol
1996;105:371-378.) (Kaiser Permanente Medical Center), which provides viable support for the use of acyclovir, an established herpes virus inhibitor. The study compared an acyclovir-prednisone group of subjects with a prednisone-placebo group and the following results were obtained: a 92% volitional motion recovery rate for the acyclovir group versus 76% for the prednisone-placebo group, and an 87% prevention rate of nerve degeneration for acyclovir-prednisone versus 70% for prednisone-placebo. Although the number of subjects was one hundred, about equally split in the 2 groups, results are both statistically significant and in agreement with other studies supporting a herpes simplex or herpes family origins of Bell's Palsy. These studies include the work of Sugita (Sugita T et al,
Facial Nerve Paralysis Induced by Herpes Simplex Virus in Mice: An Animal Model of Acute Transient Facial Paralysis, Ann Otol Rhinol Laryngol
104(7):574-581, July 1995) inducing apparent Bell's Palsy in mice with herpes simplex and the work of Murakami, pointing chiefly to herpes simplex but sometimes invoking other herpes viruses.
Further, recently there has been a significant study by M. Ikeda (Nihon University School of Medicine, Tokyo Japan) linking endothelin, a peptide of 21 amino acids with Bell's Palsy. This study is yet to receive sufficient attention, however it sheds important light on some of the immediate causal events underlying Bell's Palsy. Endothelin is an extremely potent constrictor of blood vessels, particularly smaller ones, and Ikeda maintains that impairment of microcirculation through primary and secondary ischemia in the fallopian aqueduct (and thereby drawing on the earlier work of Hilger and Blunt) is responsible, but what is new here is the role of endothelin in bringing this about. Ikeda, however, regards the etiology of Bell's Palsy as unknown or idiopathic, and does not offer any causal hypotheses for the high endothelin levels.
There are some other current therapies in addition to steroids, but they do not enjoy a similar popularity, although they are occasionally used in conjunction with it. This includes surgical decompression, more prevalent in previous decades, beginning in the thirties, although sometimes still employed (Jabor M A,
Management of Bell's Palsy, J LA State Medical Soc,
146(7): 279-283, 1996) where damage is assessed as extensive. Additionally included is electrical stimulation (also used in previous decades (Devrese P P et al.,
Electrotherapy in Facial Paralysis, ORL Otorhinolarygol Relat Spec,
1974; 36(2): 94-99) acupuncture and biofeedback (May M, et al,
Bell's Palsy: Management of Sequelae Using EMG. Rehabilitation, Bottulinum and Surgery , Am J Otol,
10(3):220-229, May 1989)). There appears to be no conclusive studies on these techniques and anecdotal evidence is at best mixed. As for surgery, it has its special hazards, while being based upon the ischemia hypothesis.
In addition to the discussed therapies designed to alleviate or minimize damage, management approaches including eye patches and artificial tears are almost invariably offered to avoid permanent eye damage. Electrical conductivity tests are also used and are of significant value in assessing permanent nerve damage of degeneration. Facial massage is sometimes also recommended to aid in circulation and avoid atrophy once muscle movement returns.
There have been 4 p
Gottlieb Rackman & Reisman P.C.
Jarvis William R. A.
LandOfFree
Therapy for herpes neurological viral conditions utilizing... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy for herpes neurological viral conditions utilizing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for herpes neurological viral conditions utilizing... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2576864